• Profile
Close

Adjuvant anastrozole vs exemestane vs letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): A randomised, phase 3 trial

The Lancet Oncology Mar 01, 2018

De Placido S, et al. - The schedule and type of aromatase inhibitors used as adjuvant treatment for hormone receptor-positive early breast cancer were determined. Patients assigned to oral anastrozole, exemestane, or letrozole tablets upfront for 5 years (upfront strategy) or oral tamoxifen for 2 years followed by oral administration of one of the three aromatase inhibitors for 3 years (switch strategy) were compared. No differences in efficacy were noted in treating patients for 5 years with aromatase inhibitors compared with the switch strategy. None of the three aromatase inhibitors was superior to the others. When deciding the optimal treatment approach in this setting, considering patient preference, tolerability, and financial constraints is recommended.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay